Literature DB >> 31073860

Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.

Yan Luo1,2, Sanaz Ameli2, Ankur Pandey2, Pegah Khoshpouri2, Mounes Aliyari Ghasabeh2, Pallavi Pandey2, Zhen Li1, Daoyu Hu1, Ihab R Kamel3,4.   

Abstract

OBJECTIVES: To evaluate the accuracy and reproducibility of semi-quantitative visual assessment of hepatic tumor burden (HTB) on MRI and to investigate its prognostic value in predicting overall survival (OS) in neuroendocrine liver metastases (NELMs) treated with transarterial chemoembolization (TACE).
METHODS: Three independent readers blinded to the quantitative HTB measurement reviewed baseline MRI in 111 NELM patients treated with TACE. Readers visually assessed and semi-quantitatively categorized HTB using the European Neuroendocrine Tumor Society (ENETS) guidelines. Quantitative HTB measured by manual segmentation was used as the reference standard. Agreements between quantitative and semi-quantitative measurement of HTB, as well as intra- and inter-reader reproducibility, were evaluated using weighted kappa coefficient and intraclass correlation coefficient (ICC). Survival analysis included the Kaplan-Meier curves and Cox regression. Harrell C-index was calculated to evaluate the prognostic value of semi-quantitative HTB for predicting OS.
RESULTS: According to quantitative HTB, 41, 29, 25, and 16 patients were categorized into ≤ 10%, 11-25%, 26-50%, and > 50% groups, respectively. Agreements between quantitative and semi-quantitative measurement of HTB by each reader (weighted kappa, 0.82-0.96), intra-reader agreement (weighted kappa, 0.95), and inter-reader agreements (weighted kappa, 0.84-0.91; ICC, 0.98) were at least substantial to almost perfect. Semi-quantitative HTB was an independent prognostic factor in NELMs treated with TACE (multivariate Cox regression, p < 0.001), with prognostic value comparable to that of quantitative HTB (Harrell C-index, 0.735 for both semi-quantitative and quantitative HTB in multivariate regression).
CONCLUSION: Semi-quantitative visual assessment of HTB using MRI is accurate and reproducible and could reliably predict OS in NELMs treated with TACE. KEY POINTS: • Semi-quantitative visual assessment of HTB using MR imaging is considerably accurate, reproducible, and efficient. • Visually assessed semi-quantitative HTB serves as an independent predictor of OS in NELMs treated with TACE.

Entities:  

Keywords:  Liver neoplasms; Magnetic resonance imaging; Neuroendocrine tumors; Reproducibility of results; Tumor burden

Mesh:

Year:  2019        PMID: 31073860     DOI: 10.1007/s00330-019-06246-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  33 in total

Review 1.  Recommendations for management of patients with neuroendocrine liver metastases.

Authors:  Andrea Frilling; Irvin M Modlin; Mark Kidd; Christopher Russell; Stefan Breitenstein; Riad Salem; Dik Kwekkeboom; Wan-yee Lau; Catherine Klersy; Valerie Vilgrain; Brian Davidson; Mark Siegler; Martyn Caplin; Enrico Solcia; Richard Schilsky
Journal:  Lancet Oncol       Date:  2014-01       Impact factor: 41.316

2.  Semi-automatic liver tumor segmentation with hidden Markov measure field model and non-parametric distribution estimation.

Authors:  Yrjö Häme; Mika Pollari
Journal:  Med Image Anal       Date:  2011-06-24       Impact factor: 8.545

3.  Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis.

Authors:  Mohammed Shaheen; Mazen Hassanain; Murad Aljiffry; Tatiana Cabrera; Prosanto Chaudhury; Eve Simoneau; Nuttawut Kongkaewpaisarn; Ayat Salman; Juan Rivera; Mohammad Jamal; Robert Lisbona; Azzam Khankan; David Valenti; Peter Metrakos
Journal:  HPB (Oxford)       Date:  2011-11-14       Impact factor: 3.647

4.  Tumor burden analysis on computed tomography by automated liver and tumor segmentation.

Authors:  Marius George Linguraru; William J Richbourg; Jianfei Liu; Jeremy M Watt; Vivek Pamulapati; Shijun Wang; Ronald M Summers
Journal:  IEEE Trans Med Imaging       Date:  2012-08-07       Impact factor: 10.048

5.  Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis.

Authors:  O Kress; H-J Wagner; M Wied; K J Klose; R Arnold; H Alfke
Journal:  Digestion       Date:  2003-10-31       Impact factor: 3.216

6.  Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.

Authors:  Mashaal Dhir; Ruchi Shrestha; Jennifer L Steel; J Wallis Marsh; Allan Tsung; Mitchel E Tublin; Nikhil B Amesur; Philip D Orons; Ernesto Santos; David A Geller
Journal:  Ann Surg Oncol       Date:  2016-09-23       Impact factor: 5.344

7.  Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think...

Authors:  Dominique Elias; Jérémie H Lefevre; Pierre Duvillard; Diane Goéré; Clarisse Dromain; Frédéric Dumont; Eric Baudin
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

8.  Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

Authors:  Anja Rinke; Michael Wittenberg; Carmen Schade-Brittinger; Behnaz Aminossadati; Erdmuthe Ronicke; Thomas M Gress; Hans-Helge Müller; Rudolf Arnold
Journal:  Neuroendocrinology       Date:  2016-01-06       Impact factor: 4.914

9.  Consensus guidelines for the management and treatment of neuroendocrine tumors.

Authors:  Pamela L Kunz; Diane Reidy-Lagunes; Lowell B Anthony; Erin M Bertino; Kari Brendtro; Jennifer A Chan; Herbert Chen; Robert T Jensen; Michelle Kang Kim; David S Klimstra; Matthew H Kulke; Eric H Liu; David C Metz; Alexandria T Phan; Rebecca S Sippel; Jonathan R Strosberg; James C Yao
Journal:  Pancreas       Date:  2013-05       Impact factor: 3.327

10.  Computing Inter-Rater Reliability for Observational Data: An Overview and Tutorial.

Authors:  Kevin A Hallgren
Journal:  Tutor Quant Methods Psychol       Date:  2012
View more
  4 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

2.  Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.

Authors:  Milena Miszczuk; Julius Chapiro; Duc Do Minh; Johanna Maria Mijntje van Breugel; Susanne Smolka; Irvin Rexha; Bruno Tegel; MingDe Lin; Lynn Jeanette Savic; Kelvin Hong; Christos Georgiades; Nariman Nezami
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-08       Impact factor: 2.797

3.  Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.

Authors:  Yiming Liu; Haikuan Liu; Wenchuan Chen; Hang Yu; Wang Yao; Wenzhe Fan; Jiaping Li; Minhu Chen; Jie Chen; Yu Wang
Journal:  Cancer Med       Date:  2022-03-14       Impact factor: 4.711

Review 4.  Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.